Clinical and Pathological Characteristics of Women With Ovarian Cancers in Syria

Ovarian Cancer Clinical Trial

Official title:

Clinical and Pathological Characteristics of Women With Ovarian Cancers, A National, Retrospective Cross-Sectional Study in Syria During the War

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT06253559
• Other study ID #: TishreenU -Ovarian Cancer
• Status: Completed
• Start date: January 1, 2017
• Est. completion date: December 24, 2023

Study information

• Verified date: February 2024
• Source: Tishreen University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

the goal of this observational study is to describe ovarian cancer epidemiology and characteristics in Syrian women, especially during the war to do more research in the future about the risk factors of ovarian cancer.

Description:

Ovarian cancer (OC) is the eighth most common cause of death worldwide, and current studies show that the death numbers caused by it will rise dramatically in the coming years. As the epidemiological features of the cancer may vary, studying these different characteristics can help us improve treatment outcomes and add preventive measures. In addition, giving special attention to these features in developing countries, or countries undergoing crisis, will help us understand the associated risk factors in these regions.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 531
• Est. completion date: December 24, 2023
• Est. primary completion date: July 31, 2021
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• female adult (age =18 years)

• primary ovarian malignancy

Exclusion Criteria:

• less than 18 years old

• women who have benign tumors or metastatic ovarian cancer.

Related Conditions & MeSH terms

• Carcinoma, Ovarian Epithelial
• Ovarian Cancer
• Ovarian Neoplasms

Locations

Country	Name	City	State
Syrian Arab Republic	Tishreen University	Latakia

Sponsors (1)

Lead Sponsor	Collaborator
Tishreen University

Country where clinical trial is conducted

Syrian Arab Republic, 

References & Publications (30)

Andrews L, Mutch DG. Hereditary Ovarian Cancer and Risk Reduction. Best Pract Res Clin Obstet Gynaecol. 2017 May;41:31-48. doi: 10.1016/j.bpobgyn.2016.10.017. Epub 2017 Jan 17. — View Citation

Arora N, Talhouk A, McAlpine JN, Law MR, Hanley GE. Long-term mortality among women with epithelial ovarian cancer: a population-based study in British Columbia, Canada. BMC Cancer. 2018 Oct 25;18(1):1039. doi: 10.1186/s12885-018-4970-9. — View Citation

Arora, T., Mullangi, S., & Lekkala, M. R. (2021). Ovarian Cancer. StatPearls. http://europepmc.org/books/NBK567760

Atallah GA, Abd Aziz NH, Teik CK, Shafiee MN, Kampan NC. New Predictive Biomarkers for Ovarian Cancer. Diagnostics (Basel). 2021 Mar 7;11(3):465. doi: 10.3390/diagnostics11030465. — View Citation

Boussios S, Karathanasi A, Zakynthinakis-Kyriakou N, Tsiouris AK, Chatziantoniou AA, Kanellos FS, Tatsi K. Ovarian carcinosarcoma: Current developments and future perspectives. Crit Rev Oncol Hematol. 2019 Feb;134:46-55. doi: 10.1016/j.critrevonc.2018.12.006. Epub 2018 Dec 24. — View Citation

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12. Erratum In: CA Cancer J Clin. 2020 Jul;70(4):313. — View Citation

Chornokur G, Amankwah EK, Schildkraut JM, Phelan CM. Global ovarian cancer health disparities. Gynecol Oncol. 2013 Apr;129(1):258-64. doi: 10.1016/j.ygyno.2012.12.016. Epub 2012 Dec 22. — View Citation

Funston G, Hamilton W, Abel G, Crosbie EJ, Rous B, Walter FM. The diagnostic performance of CA125 for the detection of ovarian and non-ovarian cancer in primary care: A population-based cohort study. PLoS Med. 2020 Oct 28;17(10):e1003295. doi: 10.1371/journal.pmed.1003295. eCollection 2020 Oct. — View Citation

Gaona-Luviano P, Medina-Gaona LA, Magana-Perez K. Epidemiology of ovarian cancer. Chin Clin Oncol. 2020 Aug;9(4):47. doi: 10.21037/cco-20-34. Epub 2020 Jun 30. — View Citation

Hayat MJ, Howlader N, Reichman ME, Edwards BK. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist. 2007 Jan;12(1):20-37. doi: 10.1634/theoncologist.12-1-20. — View Citation

Holschneider CH, Berek JS. Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol. 2000 Jul-Aug;19(1):3-10. doi: 10.1002/1098-2388(200007/08)19:13.0.co;2-s. — View Citation

Lima MA, Dos Santos L, Turri JA, Nonogaki S, Buim M, Lima JF, de Jesus Viana Pinheiro J, Bueno de Toledo Osorio CA, Soares FA, Freitas VM. Prognostic Value of ADAMTS Proteases and Their Substrates in Epithelial Ovarian Cancer. Pathobiology. 2016;83(6):316-26. doi: 10.1159/000446244. Epub 2016 Jul 1. — View Citation

Lukanova A, Kaaks R. Endogenous hormones and ovarian cancer: epidemiology and current hypotheses. Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):98-107. — View Citation

McCluggage WG. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. Pathology. 2011 Aug;43(5):420-32. doi: 10.1097/PAT.0b013e328348a6e7. — View Citation

Meena RK, Syed NA, Sheikh ZA, Guru FR, Mir MH, Banday SZ, Mp AK, Parveen S, Dar NA, Bhat GM. Patterns of Treatment and Outcomes in Epithelial Ovarian Cancer: A Retrospective North Indian Single-Institution Experience. JCO Glob Oncol. 2022 Nov;8:e2200032. doi: 10.1200/GO.22.00032. — View Citation

Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: epidemiology and risk factors. Int J Womens Health. 2019 Apr 30;11:287-299. doi: 10.2147/IJWH.S197604. eCollection 2019. — View Citation

Ovarian cancer statistics | World Cancer Research Fund International. (n.d.). Retrieved May 19, 2023, from https://www.wcrf.org/cancer-trends/ovarian-cancer-statistics/

Parazzini F, Franceschi S, La Vecchia C, Fasoli M. The epidemiology of ovarian cancer. Gynecol Oncol. 1991 Oct;43(1):9-23. doi: 10.1016/0090-8258(91)90003-n. — View Citation

Prat J. Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Arch. 2012 Mar;460(3):237-49. doi: 10.1007/s00428-012-1203-5. Epub 2012 Feb 10. — View Citation

Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. Cancer Biol Med. 2017 Feb;14(1):9-32. doi: 10.20892/j.issn.2095-3941.2016.0084. — View Citation

Saki S, Ali NR, Saki SS, AlRabeea ZS, AlRemeithi FN, Carrick FR, Abdulrahman M. Barriers to healthcare seeking, beliefs about ovarian cancer and the role of socio-economic position. A cross-sectional multilevel study in Dubai, a multicultural society. J Public Health Res. 2021 Mar 24;10(3):2073. doi: 10.4081/jphr.2021.2073. — View Citation

Shanmughapriya, S., Senthilkumar, G., Arun, S., Das, B. C., & Natarajaseenivasan, K. (2016). Risk factors for epithelial ovarian carcinoma in India: A case control study in low-incidence population. International Journal of Cancer Research, 12(1), 61-68. https://doi.org/10.3923/IJCR.2016.61.68

Syria crisis . (n.d.). Retrieved May 19, 2023, from https://www.who.int/emergencies/situations/syria-crisis

the World Cancer Research Fund (WCRF), worldwide cancer data., 2020; https://www.wcrf.org/cancer-trends/worldwide-cancer-data/ )

Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, Gaudet MM, Jemal A, Siegel RL. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018 Jul;68(4):284-296. doi: 10.3322/caac.21456. Epub 2018 May 29. — View Citation

Wentzensen N, Poole EM, Trabert B, White E, Arslan AA, Patel AV, Setiawan VW, Visvanathan K, Weiderpass E, Adami HO, Black A, Bernstein L, Brinton LA, Buring J, Butler LM, Chamosa S, Clendenen TV, Dossus L, Fortner R, Gapstur SM, Gaudet MM, Gram IT, Hartge P, Hoffman-Bolton J, Idahl A, Jones M, Kaaks R, Kirsh V, Koh WP, Lacey JV Jr, Lee IM, Lundin E, Merritt MA, Onland-Moret NC, Peters U, Poynter JN, Rinaldi S, Robien K, Rohan T, Sandler DP, Schairer C, Schouten LJ, Sjoholm LK, Sieri S, Swerdlow A, Tjonneland A, Travis R, Trichopoulou A, van den Brandt PA, Wilkens L, Wolk A, Yang HP, Zeleniuch-Jacquotte A, Tworoger SS. Ovarian Cancer Risk Factors by Histologic Subtype: An Analysis From the Ovarian Cancer Cohort Consortium. J Clin Oncol. 2016 Aug 20;34(24):2888-98. doi: 10.1200/JCO.2016.66.8178. Epub 2016 Jun 20. — View Citation

Yoneda A, Lendorf ME, Couchman JR, Multhaupt HA. Breast and ovarian cancers: a survey and possible roles for the cell surface heparan sulfate proteoglycans. J Histochem Cytochem. 2012 Jan;60(1):9-21. doi: 10.1369/0022155411428469. — View Citation

Yuan R, Zhang C, Li Q, Ji M, He N. The impact of marital status on stage at diagnosis and survival of female patients with breast and gynecologic cancers: A meta-analysis. Gynecol Oncol. 2021 Sep;162(3):778-787. doi: 10.1016/j.ygyno.2021.06.008. Epub 2021 Jun 16. — View Citation

Zhang S, Cheng C, Lin Z, Xiao L, Su X, Zheng L, Mu Y, Liao M, Ouyang R, Li W, Ma J, Cai J, Liu L, Wang D, Zeng F, Liu J. The global burden and associated factors of ovarian cancer in 1990-2019: findings from the Global Burden of Disease Study 2019. BMC Public Health. 2022 Jul 30;22(1):1455. doi: 10.1186/s12889-022-13861-y. — View Citation

Zheng G, Yu H, Kanerva A, Forsti A, Sundquist K, Hemminki K. Familial risks of ovarian cancer by age at diagnosis, proband type and histology. PLoS One. 2018 Oct 3;13(10):e0205000. doi: 10.1371/journal.pone.0205000. eCollection 2018. Erratum In: PLoS One. 2018 Oct 26;13(10):e0206721. — View Citation

* Note: There are 30 references in all — Click here to view all references

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	age	the age of patients at the time of diagnosis	jan 2017 - july 2021
Primary	ovarian cancer grade	ovarian cancer grades frequency among patients	jan 2017 - july 2021
Primary	histological type of ovarian cancer	detect the most common type of ovarian cancer	jan 2017 - july 2021
Primary	sideness of ovarian cancer	study the frequency of bilateral or unilateral ovarian cancer	jan 2017 - july 2021
Primary	Cancer Antigen-125	Cancer Antigen-125 levels, if they are normal or high in ovarian cancer.	jan 2017 - july 2021
Primary	Treatment	detect if the patient underwent surgery or chemotherapy or the both	jan 2017 - july 2021
Primary	symptoms of ovarian cancer	detect symptoms of disease at diagnosis time	jan 2017 - july 2021